PLx Pharma Inc. to Report Second Quarter 2022 Financial Results August 12, 2022, and Provide Business Update
Following the release, Company executives will host a conference call at
A live audio webcast of the call can be accessed in the Events & Presentations section of the Company’s Investor Relations website at https://ir.plxpharma.com/events-presentations/events. A replay of the webcast will be available under the same link immediately following the conclusion of the conference call and will be available for 30 days after the call.
VAZALORE is an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. VAZALORE delivers aspirin differently from plain and enteric coated aspirin products. The special complex inside the capsule is designed for targeted release of aspirin, limiting its direct contact with the stomach. VAZALORE delivers fast, reliable absorption for pain relief plus the lifesaving benefits of aspirin. To learn more about VAZALORE, please visit www.vazalore.com.
Vice President, Investor Relations
Founder & President, In-Site Communications, Inc.
Source: PLx Pharma Inc.